Which has better valuation & earnings, EWTX or MLTX?

Edgewise Therapeutics is trading at a lower price-to-earnings ratio than MoonLake Immunotherapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Edgewise Therapeutics N/A N/A -$167.79M -$1.85 N/A MoonLake Immunotherapeutics N/A N/A -$227.32M -$3.84 N/A

Is EWTX or MLTX more profitable?

Edgewise Therapeutics' return on equity of -39.01% beat MoonLake Immunotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Edgewise Therapeutics N/A -39.01% -36.96% MoonLake Immunotherapeutics N/A -82.53% -58.17%

Which has better valuation & earnings, MLTX or DYN?

Dyne Therapeutics is trading at a lower price-to-earnings ratio than MoonLake Immunotherapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MoonLake Immunotherapeutics N/A N/A -$227.32M -$3.84 N/A Dyne Therapeutics N/A N/A -$446.21M -$3.33 N/A

Is MLTX or DYN more profitable?

Dyne Therapeutics' return on equity of -64.30% beat MoonLake Immunotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets MoonLake Immunotherapeutics N/A -82.53% -58.17% Dyne Therapeutics N/A -64.30% -50.33%

Which has preferable earnings & valuation, PBLS or MLTX?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Parabilis Medicines N/A N/A N/A N/A N/A MoonLake Immunotherapeutics N/A N/A -$227.32M -$3.84 N/A

Is PBLS or MLTX more profitable?

Parabilis Medicines' return on equity of 0.00% beat MoonLake Immunotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Parabilis Medicines N/A N/A N/A MoonLake Immunotherapeutics N/A -82.53% -58.17%

Which has better earnings and valuation, MLTX or CELC?

Celcuity is trading at a lower price-to-earnings ratio than MoonLake Immunotherapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MoonLake Immunotherapeutics N/A N/A -$227.32M -$3.84 N/A Celcuity N/A N/A -$177.04M -$4.30 N/A

Is MLTX or CELC more profitable?

MoonLake Immunotherapeutics' return on equity of -82.53% beat Celcuity's return on equity. Company Net Margins Return on Equity Return on Assets MoonLake Immunotherapeutics N/A -82.53% -58.17% Celcuity N/A -350.78% -41.54%

MoonLake Immunotherapeutics (MLTX) Competitors

$15.19 +0.13 (+0.86%)

As of 04:00 PM Eastern

Compare

MLTX vs. ACAD, EWTX, DYN, PBLS, and CELC

Should you buy MoonLake Immunotherapeutics stock or one of its competitors? MoonLake Immunotherapeutics's main competitors and comparable companies include ACADIA Pharmaceuticals (ACAD), Edgewise Therapeutics (EWTX), Dyne Therapeutics (DYN), Parabilis Medicines (PBLS), and Celcuity (CELC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does MoonLake Immunotherapeutics compare to ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals (NASDAQ:ACAD) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, earnings, media sentiment, dividends, valuation and profitability.

ACADIA Pharmaceuticals has higher revenue and earnings than MoonLake Immunotherapeutics. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ACADIA Pharmaceuticals	$1.07B	4.48	$391M	$2.22	12.55
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.84	N/A

In the previous week, ACADIA Pharmaceuticals had 9 more articles in the media than MoonLake Immunotherapeutics. MarketBeat recorded 9 mentions for ACADIA Pharmaceuticals and 0 mentions for MoonLake Immunotherapeutics. ACADIA Pharmaceuticals' average media sentiment score of 1.56 beat MoonLake Immunotherapeutics' score of 0.00 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
ACADIA Pharmaceuticals	Very Positive
MoonLake Immunotherapeutics	Neutral

96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. Comparatively, 93.8% of MoonLake Immunotherapeutics shares are held by institutional investors. 26.2% of ACADIA Pharmaceuticals shares are held by insiders. Comparatively, 10.4% of MoonLake Immunotherapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

ACADIA Pharmaceuticals presently has a consensus target price of $34.36, suggesting a potential upside of 23.33%. MoonLake Immunotherapeutics has a consensus target price of $24.57, suggesting a potential upside of 61.76%. Given MoonLake Immunotherapeutics' higher possible upside, analysts plainly believe MoonLake Immunotherapeutics is more favorable than ACADIA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ACADIA Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.78
MoonLake Immunotherapeutics	3 Sell rating(s)	4 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.41

ACADIA Pharmaceuticals has a beta of 0.86, indicating that its stock price is 14% less volatile than the broader market. Comparatively, MoonLake Immunotherapeutics has a beta of 1.04, indicating that its stock price is 4% more volatile than the broader market.

ACADIA Pharmaceuticals has a net margin of 33.42% compared to MoonLake Immunotherapeutics' net margin of 0.00%. ACADIA Pharmaceuticals' return on equity of 9.03% beat MoonLake Immunotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ACADIA Pharmaceuticals	33.42%	9.03%	6.79%
MoonLake Immunotherapeutics	N/A	-82.53%	-58.17%

Summary

ACADIA Pharmaceuticals beats MoonLake Immunotherapeutics on 13 of the 15 factors compared between the two stocks.

How does MoonLake Immunotherapeutics compare to Edgewise Therapeutics?

Edgewise Therapeutics (NASDAQ:EWTX) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, analyst recommendations, media sentiment, earnings, dividends and profitability.

Edgewise Therapeutics has a beta of 0.32, indicating that its share price is 68% less volatile than the broader market. Comparatively, MoonLake Immunotherapeutics has a beta of 1.04, indicating that its share price is 4% more volatile than the broader market.

In the previous week, Edgewise Therapeutics had 8 more articles in the media than MoonLake Immunotherapeutics. MarketBeat recorded 8 mentions for Edgewise Therapeutics and 0 mentions for MoonLake Immunotherapeutics. Edgewise Therapeutics' average media sentiment score of 1.20 beat MoonLake Immunotherapeutics' score of 0.00 indicating that Edgewise Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Edgewise Therapeutics	Positive
MoonLake Immunotherapeutics	Neutral

Edgewise Therapeutics presently has a consensus target price of $50.33, suggesting a potential upside of 19.98%. MoonLake Immunotherapeutics has a consensus target price of $24.57, suggesting a potential upside of 61.76%. Given MoonLake Immunotherapeutics' higher probable upside, analysts clearly believe MoonLake Immunotherapeutics is more favorable than Edgewise Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
MoonLake Immunotherapeutics	3 Sell rating(s)	4 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.41

Edgewise Therapeutics' return on equity of -39.01% beat MoonLake Immunotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edgewise Therapeutics	N/A	-39.01%	-36.96%
MoonLake Immunotherapeutics	N/A	-82.53%	-58.17%

93.8% of MoonLake Immunotherapeutics shares are held by institutional investors. 21.3% of Edgewise Therapeutics shares are held by insiders. Comparatively, 10.4% of MoonLake Immunotherapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Edgewise Therapeutics is trading at a lower price-to-earnings ratio than MoonLake Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.85	N/A
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.84	N/A

Summary

Edgewise Therapeutics beats MoonLake Immunotherapeutics on 9 of the 14 factors compared between the two stocks.

How does MoonLake Immunotherapeutics compare to Dyne Therapeutics?

MoonLake Immunotherapeutics (NASDAQ:MLTX) and Dyne Therapeutics (NASDAQ:DYN) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

In the previous week, Dyne Therapeutics had 10 more articles in the media than MoonLake Immunotherapeutics. MarketBeat recorded 10 mentions for Dyne Therapeutics and 0 mentions for MoonLake Immunotherapeutics. Dyne Therapeutics' average media sentiment score of 1.46 beat MoonLake Immunotherapeutics' score of 0.00 indicating that Dyne Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
MoonLake Immunotherapeutics	Neutral
Dyne Therapeutics	Positive

Dyne Therapeutics is trading at a lower price-to-earnings ratio than MoonLake Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.84	N/A
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.33	N/A

93.8% of MoonLake Immunotherapeutics shares are owned by institutional investors. Comparatively, 96.7% of Dyne Therapeutics shares are owned by institutional investors. 10.4% of MoonLake Immunotherapeutics shares are owned by company insiders. Comparatively, 9.5% of Dyne Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

MoonLake Immunotherapeutics presently has a consensus price target of $24.57, suggesting a potential upside of 61.76%. Dyne Therapeutics has a consensus price target of $34.42, suggesting a potential upside of 37.94%. Given MoonLake Immunotherapeutics' higher possible upside, equities research analysts clearly believe MoonLake Immunotherapeutics is more favorable than Dyne Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MoonLake Immunotherapeutics	3 Sell rating(s)	4 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.41
Dyne Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.87

Dyne Therapeutics' return on equity of -64.30% beat MoonLake Immunotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MoonLake Immunotherapeutics	N/A	-82.53%	-58.17%
Dyne Therapeutics	N/A	-64.30%	-50.33%

MoonLake Immunotherapeutics has a beta of 1.04, meaning that its share price is 4% more volatile than the broader market. Comparatively, Dyne Therapeutics has a beta of 1.08, meaning that its share price is 8% more volatile than the broader market.

Summary

Dyne Therapeutics beats MoonLake Immunotherapeutics on 9 of the 13 factors compared between the two stocks.

How does MoonLake Immunotherapeutics compare to Parabilis Medicines?

Parabilis Medicines (NASDAQ:PBLS) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, risk, institutional ownership, valuation, earnings and analyst recommendations.

93.8% of MoonLake Immunotherapeutics shares are owned by institutional investors. 10.4% of MoonLake Immunotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Parabilis Medicines presently has a consensus price target of $41.67, suggesting a potential upside of 2.25%. MoonLake Immunotherapeutics has a consensus price target of $24.57, suggesting a potential upside of 61.76%. Given MoonLake Immunotherapeutics' higher probable upside, analysts plainly believe MoonLake Immunotherapeutics is more favorable than Parabilis Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Parabilis Medicines	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.00
MoonLake Immunotherapeutics	3 Sell rating(s)	4 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.41

Parabilis Medicines' return on equity of 0.00% beat MoonLake Immunotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Parabilis Medicines	N/A	N/A	N/A
MoonLake Immunotherapeutics	N/A	-82.53%	-58.17%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Parabilis Medicines	N/A	N/A	N/A	N/A	N/A
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.84	N/A

In the previous week, Parabilis Medicines had 6 more articles in the media than MoonLake Immunotherapeutics. MarketBeat recorded 6 mentions for Parabilis Medicines and 0 mentions for MoonLake Immunotherapeutics. Parabilis Medicines' average media sentiment score of 1.43 beat MoonLake Immunotherapeutics' score of 0.00 indicating that Parabilis Medicines is being referred to more favorably in the media.

Company	Overall Sentiment
Parabilis Medicines	Positive
MoonLake Immunotherapeutics	Neutral

Summary

Parabilis Medicines beats MoonLake Immunotherapeutics on 6 of the 10 factors compared between the two stocks.

How does MoonLake Immunotherapeutics compare to Celcuity?

MoonLake Immunotherapeutics (NASDAQ:MLTX) and Celcuity (NASDAQ:CELC) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability.

MoonLake Immunotherapeutics' return on equity of -82.53% beat Celcuity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MoonLake Immunotherapeutics	N/A	-82.53%	-58.17%
Celcuity	N/A	-350.78%	-41.54%

Celcuity is trading at a lower price-to-earnings ratio than MoonLake Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.84	N/A
Celcuity	N/A	N/A	-$177.04M	-$4.30	N/A

In the previous week, Celcuity had 9 more articles in the media than MoonLake Immunotherapeutics. MarketBeat recorded 9 mentions for Celcuity and 0 mentions for MoonLake Immunotherapeutics. Celcuity's average media sentiment score of 1.26 beat MoonLake Immunotherapeutics' score of 0.00 indicating that Celcuity is being referred to more favorably in the news media.

Company	Overall Sentiment
MoonLake Immunotherapeutics	Neutral
Celcuity	Positive

93.8% of MoonLake Immunotherapeutics shares are held by institutional investors. Comparatively, 63.3% of Celcuity shares are held by institutional investors. 10.4% of MoonLake Immunotherapeutics shares are held by insiders. Comparatively, 13.3% of Celcuity shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

MoonLake Immunotherapeutics has a beta of 1.04, suggesting that its share price is 4% more volatile than the broader market. Comparatively, Celcuity has a beta of 0.19, suggesting that its share price is 81% less volatile than the broader market.

MoonLake Immunotherapeutics presently has a consensus price target of $24.57, suggesting a potential upside of 61.76%. Celcuity has a consensus price target of $154.55, suggesting a potential upside of 60.27%. Given MoonLake Immunotherapeutics' higher probable upside, analysts clearly believe MoonLake Immunotherapeutics is more favorable than Celcuity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MoonLake Immunotherapeutics	3 Sell rating(s)	4 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.41
Celcuity	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

Summary

MoonLake Immunotherapeutics and Celcuity tied by winning 6 of the 12 factors compared between the two stocks.

Get MoonLake Immunotherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MLTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MLTX vs. The Competition

Export

Metric	MoonLake Immunotherapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.29B	$4.02B	$7.25B	$12.89B
Dividend Yield	N/A	3.61%	2.53%	8.57%
P/E Ratio	-3.96	12.72	273.59	25.45
Price / Sales	N/A	1,361.39	675.80	123.67
Price / Cash	N/A	105.29	76.98	52.10
Price / Book	3.02	16.29	12.89	6.14
Net Income	-$227.32M	-$22.72M	$3.47B	$349.01M
7 Day Performance	-2.19%	-1.38%	-0.33%	-1.47%
1 Month Performance	-12.70%	11.06%	6.51%	2.47%
1 Year Performance	-74.47%	53.71%	25.19%	15.84%

MoonLake Immunotherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MLTX MoonLake Immunotherapeutics	1.8247 of 5 stars	$15.19 +0.9%	$24.57 +61.8%	-74.3%	$1.29B	N/A	N/A	2
ACAD ACADIA Pharmaceuticals	4.8325 of 5 stars	$30.37 +2.4%	$34.36 +13.1%	+12.6%	$5.23B	$1.07B	13.67	510
EWTX Edgewise Therapeutics	3.419 of 5 stars	$45.30 +1.3%	$50.33 +11.1%	+182.5%	$4.92B	N/A	N/A	60	News Coverage Positive News
DYN Dyne Therapeutics	3.6554 of 5 stars	$26.19 +0.8%	$34.42 +31.4%	+86.2%	$4.89B	N/A	N/A	100	News Coverage Positive News
PBLS Parabilis Medicines	2.6312 of 5 stars	$39.58 +3.0%	$41.67 +5.3%	N/A	$4.89B	N/A	N/A	N/A	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MLTX) was last updated on 9/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MoonLake Immunotherapeutics (MLTX) Competitors

MLTX vs. ACAD, EWTX, DYN, PBLS, and CELC

How does MoonLake Immunotherapeutics compare to ACADIA Pharmaceuticals?

Summary

How does MoonLake Immunotherapeutics compare to Edgewise Therapeutics?

Summary

How does MoonLake Immunotherapeutics compare to Dyne Therapeutics?

Summary

How does MoonLake Immunotherapeutics compare to Parabilis Medicines?

Summary

How does MoonLake Immunotherapeutics compare to Celcuity?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MLTX vs. The Competition

MoonLake Immunotherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MoonLake Immunotherapeutics (MLTX) Competitors

MLTX vs. ACAD, EWTX, DYN, PBLS, and CELC

How does MoonLake Immunotherapeutics compare to ACADIA Pharmaceuticals?

Which has preferable valuation and earnings, ACAD or MLTX?

Does the media favor ACAD or MLTX?

Do insiders & institutionals believe in ACAD or MLTX?

Do analysts rate ACAD or MLTX?

Which has more risk and volatility, ACAD or MLTX?

Is ACAD or MLTX more profitable?

Summary

How does MoonLake Immunotherapeutics compare to Edgewise Therapeutics?

Which has more volatility & risk, EWTX or MLTX?

Does the media refer more to EWTX or MLTX?

Do analysts recommend EWTX or MLTX?

Is EWTX or MLTX more profitable?

Do insiders & institutionals believe in EWTX or MLTX?

Which has better valuation & earnings, EWTX or MLTX?

Summary

How does MoonLake Immunotherapeutics compare to Dyne Therapeutics?

Does the media favor MLTX or DYN?

Which has better valuation & earnings, MLTX or DYN?

Do insiders and institutionals hold more shares of MLTX or DYN?

Do analysts recommend MLTX or DYN?

Is MLTX or DYN more profitable?

Which has more volatility and risk, MLTX or DYN?

Summary

How does MoonLake Immunotherapeutics compare to Parabilis Medicines?

Do institutionals and insiders hold more shares of PBLS or MLTX?

Do analysts recommend PBLS or MLTX?

Is PBLS or MLTX more profitable?

Which has preferable earnings & valuation, PBLS or MLTX?

Does the media refer more to PBLS or MLTX?

Summary

How does MoonLake Immunotherapeutics compare to Celcuity?

Is MLTX or CELC more profitable?

Which has better earnings and valuation, MLTX or CELC?

Does the media prefer MLTX or CELC?

Do insiders and institutionals hold more shares of MLTX or CELC?

Which has more risk and volatility, MLTX or CELC?

Do analysts prefer MLTX or CELC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MLTX vs. The Competition

MoonLake Immunotherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools